Clinical Trial Update: Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of a triple therapy (Sonrotoclax, Rituximab, and Zanubrutinib) for chronic lymphocytic leukemia, small lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Sonrotoclax
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Status: RECRUITING